Abstract
Three patients with chronic renal failure on maintenance haemodialysis have been treated with 1 alpha-hydroxycholecalciferol (1 alpha-OHCC), a synthetic vitamin D analogue. A daily dose of 2 mug by mouth produced a significant increase in both calcium absorption from the gastrointestinal tract and calcium content of bone. Treatment with 1 alpha-OHCC appears to be effective in cases of metabolic bone disease associated with chronic renal failure.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- ANDERSON J., OSBORN S. B., TOMLINSON R. W., NEWTON D., RUNDO J., SALMON L., SMITH J. W. NEUTRON-ACTIVATION ANALYSIS IN MAN IN VIVO. A NEW TECHNIQUE IN MEDICAL INVESTIGATION. Lancet. 1964 Dec 5;2(7371):1201–1205. doi: 10.1016/s0140-6736(64)91041-4. [DOI] [PubMed] [Google Scholar]
- Boyle I. T., Miravet L., Gray R. W., Holick M. F., Deluca H. F. The response of intestinal calcium transport to 25-hydroxy and 1,25-dihydroxy vitamin D in nephrectomized rats. Endocrinology. 1972 Mar;90(3):605–608. doi: 10.1210/endo-90-3-605. [DOI] [PubMed] [Google Scholar]
- Brickman A. S., Coburn J. W., Norman A. W. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. N Engl J Med. 1972 Nov 2;287(18):891–895. doi: 10.1056/NEJM197211022871801. [DOI] [PubMed] [Google Scholar]
- Brickman A. S., Norman A. W. Treatment of renal osteodystrophy with calciferol (vitamin D) and related steroids. Kidney Int. 1973 Aug;4(2):161–167. doi: 10.1038/ki.1973.95. [DOI] [PubMed] [Google Scholar]
- Catto G. R., McIntosh J. A., Macleod M. Partial body neutron activation analysis in vivo: a new approach to the investigation of metabolic bone disease. Phys Med Biol. 1973 Jul;18(4):508–517. doi: 10.1088/0031-9155/18/4/003. [DOI] [PubMed] [Google Scholar]
- Chalmers T. M., Hunter J. O., Davie M. W., Szaz K. F., Pelc B., Kodicek E. 1-Alpha-hydroxycholecalciferol as a substitute for the kidney hormone 1,25-dihydroxycholecalciferol in chronic renal failure. Lancet. 1973 Sep 29;2(7831):696–699. doi: 10.1016/s0140-6736(73)92536-1. [DOI] [PubMed] [Google Scholar]
- Coburn J. W., Hartenbower D. L., Massry S. G. Intestinal absorption of calcium and the effect of renal insufficiency. Kidney Int. 1973 Aug;4(2):96–104. doi: 10.1038/ki.1973.88. [DOI] [PubMed] [Google Scholar]
- Cohn S. H., Cinque T. J., Dombrowski C. S., Letteri J. M. Determination of body composition by neutron activation analysis in patient with renal failure. J Lab Clin Med. 1972 Jun;79(6):978–994. [PubMed] [Google Scholar]
- DENT C. E., HARPER C. M., PHILPOT G. R. The treatment of renal-glomerular osteodystrophy. Q J Med. 1961 Jan;30:1–31. [PubMed] [Google Scholar]
- Davies J. L., Andrews G. S., Miller R., Owen H. G. Comparison of the stannous chloride and vanadate methods for estimation of serum inorganic phosphorus by use of the "SMA 12-60". Clin Chem. 1973 Apr;19(4):411–414. [PubMed] [Google Scholar]
- DeLuca H. F. The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D 3 , a calcium-mobilizing hormone. N Engl J Med. 1973 Aug 16;289(7):359–365. doi: 10.1056/NEJM197308162890710. [DOI] [PubMed] [Google Scholar]
- FLETCHER R. F., JONES J. H., MORGAN D. B. BONE DISEASE IN CHRONIC RENAL FAILURE. Q J Med. 1963 Oct;32:321–329. [PubMed] [Google Scholar]
- Fraser D. R., Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970 Nov 21;228(5273):764–766. doi: 10.1038/228764a0. [DOI] [PubMed] [Google Scholar]
- Fremlin J. H. Determination of whole-body calcium by neutron activation analysis in vivo. Semin Nucl Med. 1972 Jan;2(1):86–93. doi: 10.1016/s0001-2998(72)80009-6. [DOI] [PubMed] [Google Scholar]
- Henderson R. G., Russell R. G., Ledingham J. G., Smith R., Oliver D. O., Walton R. J., Small D. G., Preston C., Warner G. T. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet. 1974 Mar 9;1(7854):379–384. doi: 10.1016/s0140-6736(74)93149-3. [DOI] [PubMed] [Google Scholar]
- Holick M. F., Semmler E. J., Schnoes H. K., DeLuca H. F. 1 -Hydroxy derivative of vitamin D 3 : a highly potent analog of 1 ,25-dihydroxyvitamin D 3 . Science. 1973 Apr 15;180(4082):190–191. doi: 10.1126/science.180.4082.190. [DOI] [PubMed] [Google Scholar]
- Mawer E. B., Taylor C. M., Backhouse J., Lumb G. A., Stanbury S. W. Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet. 1973 Mar 24;1(7804):626–628. doi: 10.1016/s0140-6736(73)92197-1. [DOI] [PubMed] [Google Scholar]
- Nelp W. B., Palmer H. E., Murano R., Pailthorp K., Hinn G. M., Rich C., Williams J. L., Rudd T. G., Denney J. D. Measurement of total body calcium (bone mass) in vivo with the use of total body neutron activation analysis. J Lab Clin Med. 1970 Jul;76(1):151–162. [PubMed] [Google Scholar]
- Ogg C. S. Parathyroidectomy in the treatment of secondary renal hyperparathyroidism. Kidney Int. 1973 Aug;4(2):168–173. doi: 10.1038/ki.1973.96. [DOI] [PubMed] [Google Scholar]
- Peacock M., Gallagher J. C., Nordin B. E. Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man. Lancet. 1974 Mar 9;1(7854):385–389. doi: 10.1016/s0140-6736(74)93150-x. [DOI] [PubMed] [Google Scholar]
- STANBURY S. W. Azotaemic renal osteodystrophy. Br Med Bull. 1957 Jan;13(1):57–60. doi: 10.1093/oxfordjournals.bmb.a069572. [DOI] [PubMed] [Google Scholar]
- Tripp E. J., MacKay E. H. Silver staining of bone prior to decalcification for quantitative determination of osteoid in sections. Stain Technol. 1972 May;47(3):129–136. doi: 10.3109/10520297209116467. [DOI] [PubMed] [Google Scholar]
- WILLIAMS J. A., NICHOLSON G. I. A modified bone-biopsy drill for outpatient use. Lancet. 1963 Jun 29;1(7296):1408–1408. doi: 10.1016/s0140-6736(63)92059-2. [DOI] [PubMed] [Google Scholar]